LY 303511

CAT:
804-HY-15643
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
LY 303511 - image 1

LY 303511

  • Description :

    LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K+ currents (IC50=64.6±9.1 μM) in MIN6 insulinoma cells.
  • UNSPSC :

    12352005
  • Hazard Statement :

    H302
  • Target :

    Potassium Channel; TNF Receptor
  • Type :

    Reference compound
  • Related Pathways :

    Apoptosis; Membrane Transporter/Ion Channel
  • Applications :

    Cancer-Kinase/protease
  • Field of Research :

    Cancer
  • Assay Protocol :

    https://www.medchemexpress.com/LY-303511.html
  • Solubility :

    10 mM in DMSO
  • Smiles :

    O=C1C=C(N2CCNCC2)OC3=C(C4=CC=CC=C4)C=CC=C13
  • Molecular Formula :

    C19H18N2O2
  • Molecular Weight :

    306.36
  • Precautions :

    P264-P270-P330-P501
  • References & Citations :

    [1]Bodenstine TM, et al. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Res. 2010 Dec 1;70 (23) :10002-11.|[2]Shenoy K, et al. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 2009 Mar 1;69 (5) :1941-50.|[3]El-Kholy W, Macdonald PE, Lin JH, The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K (V) currents via a direct mechanism. FASEB J. 2003 Apr;17 (6) :720-2.|[4]Kristof AS, et al. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR) - and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther. 2005 Sep;314 (3) :1134-43.
  • Shipping Conditions :

    Room temperature
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    No Development Reported
  • Citation 01 :

    Int J Mol Sci. 2023 Jul 28;24 (15) :12079.|bioRxiv. 2025 Nov 8.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Proc Natl Acad Sci U S A. 2024 Nov 19;121 (47) :e2405534121.
  • CAS Number :

    [154447-38-8]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide